Fig. 3: The RNA level of MFAP2 in clinical samples and sequencing analysis on MFAP2 knockdown cell lines. | Oncogenesis

Fig. 3: The RNA level of MFAP2 in clinical samples and sequencing analysis on MFAP2 knockdown cell lines.

From: MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway

Fig. 3

a Lysates from paired GC and adjacent normal tissues were analyzed by qPCR for the detection of MFAP2. GAPDH was used as a loading control. Each value presents the mean ± S.E.M. of three independent triplicate experiments. b Western blotting analysis of MFAP2 expression in 14 pairs of GC and adjacent tissues. c Western blotting analysis of MFAP2 expression in 4 GC cell lines, namely, HGC-27, SGC-7901, MGC-803, and AGS, and the normal gastric cell line GSE-1. GAPDH was used as a loading control. d The knockdown of MFAP2 in cells was affirmed by western blot. e The knockdown of MFAP2 in cells was affirmed by real-time RT-PCR. RNA sequencing using Illumina HumanHT-12 V4.0 expression beadchip was applied to assess the change of gene expression profile after MFAP2 knockdown in AGS cell line. **P < 0.01 vs. NC. f Cluster analysis of gene expression profile after MFAP2 knockdown. Downregulated (green) and upregulated genes (red) were identified. g Significantly changed pathways were identified based on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database using the Gene Cloud of Biotechnology Information.

Back to article page